Trial Profile

A Phase 2B Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of 3 Dosages of SAP-001 in Combination With Standard of Care in Adult Subjects With Gout

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SAP 001 (Primary)
Indications Gout; Gouty arthritis
Focus Therapeutic Use
Acronyms RID-GOUT
Sponsors Shanton Pharma

Most Recent Events

19 May 2025 According to a Shanton Pharma media release, company will be presenting topline data from this study at the annual EULAR Congress in Barcelona on June 14.
28 Mar 2025 Topline results presented in the Shanton Pharma Media Release
14 Nov 2024 Planned End Date changed from 30 Jan 2025 to 1 Feb 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com